Pancreatic Disorders News

BOSTON — Fewer patients hospitalized for acute pulmonary embolism with pancreatic cancer died in 2020 compared with rates in 2001, according to a presentation at the CHEST Annual Meeting.

PHILADELPHIA — No significant differences were observed in post-endoscopic retrograde cholangiopancreatography pancreatitis with prophylactic diclofenac vs. indomethacin, with researchers also reporting savings of nearly $133,000.

PHILADELPHIA — Patients with type 2 diabetes on glucagon-like peptide-1 receptor agonists had significantly lower risk for pancreatic cancer compared with those on other antidiabetic therapies, regardless of weight, according to data.

PHILADELPHIA — An AI model achieved high accuracy in detecting and distinguishing between cystic and solid pancreatic focal lesions during endoscopic ultrasound procedures, according to data presented at the ACG Annual Scientific Meeting.

Adults with obesity who underwent bariatric surgery were less likely to develop pancreatic cancer than those who with obesity who did not have bariatric surgery, researchers reported.

A simple median waiting time that did not account for censoring, death and other competing events underestimated time to organ transplantation by up to 61% compared with a competing-risk model, according to a study conducted in Switzerland.

In patients with persistent chylomicronemia, plozasiran, a small interfering RNA therapy, was associated with lower triglyceride levels and reduced risk for pancreatitis, researchers reported at the European Society of Cardiology Congress.

Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.

The FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ plozasiran, coupled with diet, to decrease triglycerides in patients with familial chylomicronemia syndrome, according to a company release.